Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.
Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM.
Lacouture ME, et al. Among authors: moy ap.
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3431. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38652814